Get the Stockscreener App
102.10
0.55%
-0.56
After Hours:
102.10
Rhythm Pharmaceuticals Inc stock is traded at $102.10, with a volume of 467.13K.
It is down -0.55% in the last 24 hours and down -5.07% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
See More
Previous Close:
$102.66
Open:
$103.92
24h Volume:
467.13K
Relative Volume:
0.60
Market Cap:
$7.00B
Revenue:
$217.17M
Net Income/Loss:
$-202.68M
P/E Ratio:
-44.34
EPS:
-2.3028
Net Cash Flow:
$-156.63M
1W Performance:
-4.22%
1M Performance:
-5.07%
6M Performance:
-0.75%
1Y Performance:
+16.99%
1-Day Range:
$101.49
$104.87
1-Week Range:
$101.04
$107.45
52-Week Range:
$74.50
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
102.10 | 7.04B | 217.17M | -202.68M | -156.63M | -2.3028 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 120.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.84B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.13B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 35.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | RBC Capital Mkts | Outperform |
| Nov-25-25 | Initiated | Citigroup | Buy |
| Nov-05-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-10-25 | Initiated | Goldman | Buy |
| Jul-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Rhythm Pharmaceuticals (RYTM) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals, Inc. (RYTM) stock price, news, quote and history - Yahoo Finance UK
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm - Morningstar
RYTM stock trades around recent range as Rhythm Pharmaceuticals highlights setmelanotide growth - AD HOC NEWS
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - The Manila Times
Price-Driven Insight from (RYTM) for Rule-Based Strategy - Stock Traders Daily
Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Strong Buy Ratings Signal Potential 31% Upside - DirectorsTalk Interviews
Rhythm Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Rhythm Pharmaceuticals Inc to Discuss Interim Six-Month Phase 2 Results Evaluating Setmelanotide Call Transcript - GuruFocus
Law firm probes Rhythm Pharmaceuticals officers for possible self-dealing harming shareholders - Pluang
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm - GlobeNewswire Inc.
Wells Fargo Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $155 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – BMV:RYTM - TradingView
Does NEJM-Validated TRANSCEND Data on Setmelanotide Reshape the Bull Case for Rhythm Pharmaceuticals (RYTM)? - Sahm
Rhythm Pharmaceuticals (RYTM) Edges Higher, Nears Key Resistance LevelSymmetrical Triangle - dars.gov.et
Citizens reiterates Rhythm Pharmaceuticals stock rating on strong Imcivree launch data - Investing.com Canada
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 28.91% Upside Potential in Biotechnology - DirectorsTalk Interviews
Enterprise value to EBITDA forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM - TradingView
Price to earnings forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM - TradingView
Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – XETR:1RV - TradingView
Rhythm Pharmaceuticals (RYTM) On TRANSCEND And New Approvals, Buying Opportunity Or Priced In? - Sahm
Rhythm Pharmaceuticals Inc. announced that the results of its Phase 3 Transcend clinical trial for acquired hypothalamic obesity have been published in the top international medical journal, The New England Journal of Medicine. - Bitget
Rhythm Pharmaceuticals Announces NEJM Publication of Phase 3 TRANSCEND Trial Results for Setmelanotide in Acquired Hypothalamic Obesity - Quiver Quantitative
Rhythm Pharmaceuticals Announces The New England Journal of - GlobeNewswire
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity - Yahoo Finance UK
CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $151 - Moomoo
RYTM Maintained by RBC Capital -- Price Target Raised to $141.00 - GuruFocus
Rhythm Pharmaceuticals balances obesity-drug growth prospects and biotech risks - Ad-hoc-news.de
RBC Capital Adjusts Rhythm Pharmaceuticals Price Target to $141 From $137, Maintains Outperform Rating - marketscreener.com
Rhythm Pharmaceuticals Announces New Data Presentations In Acquired Hypothalamic Obesity At Pediatric Endocrine Society >RYTM - Moomoo
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech Contender with 22% Upside Potential - DirectorsTalk Interviews
Price to sales forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM - TradingView
RYTMRhythm Pharmaceuticals Inc Options - Finviz
Rhythm Pharmaceuticals announces public offering of common stock - MSN
Rhythm Pharmaceuticals (RYTM) CSO exercises RSUs, 2,150 shares withheld for taxes - Stock Titan
Rhythm Pharmaceuticals Stock On Fire: Up 28% With 12-Day Winning Streak - Trefis
Rhythm Pharmaceuticals stock trades up to $111.03 as Rhythm Pharmaceuticals closes offices for July 4th break - Traders Union
Rhythm Pharmaceuticals Stock Surges 28%, With A 12-Day Winning Spree - Trefis
Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results? - Insider Monkey
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech with Promising Upside and Strong Buy Ratings - DirectorsTalk Interviews
Rhythm Pharmaceuticals Stock Rockets 28% With 11-Day Winning Streak - Trefis
(RYTM) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Rhythm Pharmaceuticals highlights obesity pipeline, shares track sector peers - Ad-hoc-news.de
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):